Clinical Trial Detail


Missing content? – Request curation!

Request curation for specific Genes, variants, or PubMed publications.

Have questions, comments or suggestions? - Let us know!

Email us at :

NCT ID NCT04656951
Title Daratumumab for First Line Treatment of Transplant-ineligible Myeloma Patients Followed by Daratumumab Re-treatment at First Relapse (GMMG-DADA)
Recruitment Recruiting
Gender both
Phase Phase II
Variant Requirements No
Sponsors University of Cologne
Age Groups: adult | senior
Covered Countries DEU

No variant requirements are available.